Association between preoperative serum total cholesterol level and biochemical recurrence in prostate cancer patients who underwent radical prostatectomy.
The aim of this study was to investigate the association between serum total cholesterol (TC) level and biochemical recurrence (BCR) following radical prostatectomy (RP). The study included 562 patients with T1-3N0M0 prostate cancer, who underwent RP at our institution between 2002 and 2010. No patients received neoadjuvant and/or adjuvant therapy. The associations between preoperative TC level, clinicopathological factors and BCR were assessed using univariate and multivariate analyses. During follow-up (mean, 54.0 months), 168 patients (168/562, 29.9%) experienced BCR, with a 5-year BCR-free rate of 67.2%. Of the clinicopathological characteristics investigated, statin use and lymphovascular invasion (LVI) status were associated with lower TC level (P=0.003 and P=0.014, respectively). In the univariate analysis, a higher serum prostate-specific antigen (PSA) level at diagnosis, extracapsular extension, positive surgical margin, seminal vesicle invasion, LVI, perineural invasion, higher Gleason score (GS ≥8) based on the RP specimen, increased body mass index, and low preoperative TC level, were significantly associated with BCR. In the multivariate analysis, the TC level was an independent predictor of BCR (hazard ratio = 0.925 per 10 mg/dl; 95% confidence interval: 0.879-0.973; P=0.003), as was the serum PSA level, extracapsular extension, positive surgical margin and the GS. Low preoperative serum TC levels were associated with an increased risk of BCR among prostate cancer patients who underwent RP. Our findings suggest that the preoperative serum TC level may provide important clinical information that may prove to be useful in patient counseling.
Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan.
Yoshio
Y
Ohno
Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan.
Makoto
M
Ohori
Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan.
Jun
J
Nakashima
Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan.
Hidenori
H
Okubo
Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan.
Naoya
N
Satake
Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan.
Takeshi
T
Hashimoto
Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan.
Masaaki
M
Tachibana
prostate cancer; prostate-specific antigen; prostatectomy; recurrence; total cholesterol